Education - Oncidium Foundation (original) (raw)

Skip to content

Educationoncidiumfoundation_brbf8h2024-01-05T12:40:01+00:00

Radiotherapeutic Target Mechanism Radionuclide Ligand/Carrier Indication Status Radiation Type hf:tax:target_mechanism hf:tax:isotope hf:tax:ligand_carrier hf:tax:indication hf:tax:status hf:tax:leading_emitter
Ac-225-DOTA-SP Substance P 225Ac Substance P Glioblastoma In Clinical development alpha (α) Read more substance-p 225ac substance-p glioblastoma in-clinical-development alpha-%ce%b1
Ac-225-DOTA-YS5 CD46 225Ac IgG1 Prostate Cancer Early stage alpha (α) Read more cd46 225ac igg1 prostate-cancer early-stage alpha-%ce%b1
Ac-225-DOTATOC Somatostatin receptors 225Ac Edotreotide Neuroendocrine Tumor (NET) Early stage alpha (α) Read more somatostatin-receptors 225ac edotreotide neuroendocrine-tumor-net early-stage alpha-%ce%b1
Ac-225-DOTAZOL Bones 225Ac n/a Bone pain palliation Early stage alpha (α) Read more bones 225ac n-a bone-pain-palliation early-stage alpha-%ce%b1
Ac-225-FPI-1434 IGF-1R 225Ac FPI-1434 Solid Tumors In Clinical development alpha (α) Read more igf-1r 225ac fpi-1434 solid-tumors in-clinical-development alpha-%ce%b1
Ac-225-FPI-2059 NTSR1 225Ac 3BP-227 Solid Tumors Early stage alpha (α) Read more ntsr1 225ac 3bp-227 solid-tumors early-stage alpha-%ce%b1
Ac-225-FPI-2068 EGFR 225Ac Fab Solid Tumors Early stage alpha (α) Read more egfr 225ac fab solid-tumors early-stage alpha-%ce%b1
Ac-225-FPI-2265 PSMA 225Ac PSMA-I&T Prostate Cancer In Clinical development alpha (α) Read more psma 225ac psma-it prostate-cancer in-clinical-development alpha-%ce%b1
Ac-225-Lintuzumab (Ac-225 Actimab-A™) CD33 225Ac Lintuzumab Acute Myeloid Leukemia (AML), Colon cancer In Clinical development alpha (α) Read more cd33 225ac lintuzumab acute-myeloid-leukemia-aml colon-cancer in-clinical-development alpha-%ce%b1
Ac-225-MTI-201 Melanocortin-1 225Ac Fab Uveal Cancer Early stage alpha (α) Read more melanocortin-1 225ac fab uveal-cancer early-stage alpha-%ce%b1
Ac-225-PSMA-617 PSMA 225Ac Vipivotide Prostate Cancer In Clinical development alpha (α) Read more psma 225ac vipivotide prostate-cancer in-clinical-development alpha-%ce%b1
Ac-225-Rosopatamab PSMA 225Ac CONV-01-α Prostate Cancer In Clinical development alpha (α) Read more psma 225ac conv-01-%ce%b1 prostate-cancer in-clinical-development alpha-%ce%b1
Ac-225-RYZ101 Somatostatin receptors 225Ac Edotreotate Solid Tumors In Clinical development alpha (α) Read more somatostatin-receptors 225ac edotreotate solid-tumors in-clinical-development alpha-%ce%b1
At-211-81C6 mAb (Neuradiab) Tenascin 211At 81C6 mAb Brain Cancer On hold or discontinued alpha (α) Read more tenascin 211at 81c6-mab brain-cancer on-hold-or-discontinued alpha-%ce%b1
At-211-BC8-B10 CD45 211At BC8 Acute leukemia, Acute Myeloid Leukemia (AML), Myelodisplastic syndrome Early stage alpha (α) Read more cd45 211at bc8 acute-leukemia acute-myeloid-leukemia-aml myelodisplastic-syndrome early-stage alpha-%ce%b1
At-211-MABG Adrenergic tissues 211At Iobenguane Paragangliomas, Pheochromocytoma In Clinical development alpha (α) Read more adrenergic-tissues 211at iobenguane paragangliomas pheochromocytoma in-clinical-development alpha-%ce%b1
At-211-MX35-F(ab’)-2 OVCAR-3 211At MX35-F(ab’)2 Ovarian Cancer On hold or discontinued alpha (α) Read more ovcar-3 211at mx35-fab2 ovarian-cancer on-hold-or-discontinued alpha-%ce%b1
At-211-NaAt Thyroid tissues 211At n/a Thyroid Cancer In Clinical development beta (β–) Read more thyroid-tissues 211at n-a thyroid-cancer in-clinical-development beta-%ce%b2
At-211-Parthanatine PARP1 211At Peptide Neuroblastoma Early stage alpha (α) Read more parp1 211at peptide neuroblastoma early-stage alpha-%ce%b1
Bi-213-DOTATOC Somatostatin receptors 213Bi Edotreotide Neuroendocrine Tumor (NET) Early stage alpha (α) Read more somatostatin-receptors 213bi edotreotide neuroendocrine-tumor-net early-stage alpha-%ce%b1
Bi-213-Lintuzumab (Bi-213 Bismab-A™) CD33 213Bi Lintuzumab Non-Hodgkin's lymphoma (NHL) On hold or discontinued alpha (α) Read more cd33 213bi lintuzumab non-hodgkins-lymphoma-nhl on-hold-or-discontinued alpha-%ce%b1
Cu-64-Diasparagine (CuASP) DNA 64Cu n/a Brain Cancer On hold or discontinued C.E. (Conversion Electron) Read more dna 64cu n-a brain-cancer on-hold-or-discontinued c-e-conversion-electron
Cu-67-SAR-bisPSMA PSMA 67Cu PSMA Prostate Cancer Early stage beta (β–) Read more psma 67cu psma prostate-cancer early-stage beta-%ce%b2
Cu-67-SARTATE Somatostatin receptors 67Cu Sartate Meningioma, Neuroblastoma, Neuroendocrine Tumor (NET) In Clinical development beta (β–) Read more somatostatin-receptors 67cu sartate meningioma neuroblastoma neuroendocrine-tumor-net in-clinical-development beta-%ce%b2
Er-169-Erbium Citrate Brachytherapy 169Er n/a Rheumatology Marketed beta (β–) Read more brachytherapy 169er n-a rheumatology marketed beta-%ce%b2
Ho-166- Microspheres Brachytherapy 166Ho n/a Hepatocarcinoma Marketed beta (β–) Read more brachytherapy 166ho n-a hepatocarcinoma marketed beta-%ce%b2
Ho-166-Chitosan Brachytherapy 166Ho n/a Hepatocarcinoma, Melanoma, Prostate Cancer, Rheumatology, Solid Tumors Marketed beta (β–) Read more brachytherapy 166ho n-a hepatocarcinoma melanoma prostate-cancer rheumatology solid-tumors marketed beta-%ce%b2
Ho-166-Phytate Brachytherapy 166Ho n/a Rheumatology On hold or discontinued beta (β–) Read more brachytherapy 166ho n-a rheumatology on-hold-or-discontinued beta-%ce%b2
I-131-81C6 mAb (Neuradiab™) Tenascin 131I 81C6 mAb Brain Cancer On hold or discontinued beta (β–) Read more tenascin 131i 81c6-mab brain-cancer on-hold-or-discontinued beta-%ce%b2
I-131-Apamistamab (Iomab-B™) CD45 131I Apamistamab Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Hodgkin's Lymphoma (HL), Myelodysplastic Syndrome (MDS), Non-Hodgkin's lymphoma (NHL) In Clinical development beta (β–) Read more cd45 131i apamistamab acute-lymphoblastic-leukemia-all acute-myeloid-leukemia-aml hodgkins-lymphoma-hl myelodysplastic-syndrome-mds non-hodgkins-lymphoma-nhl in-clinical-development beta-%ce%b2
I-131-BA52 Melanin 131I BA52 Melanoma On hold or discontinued beta (β–) Read more melanin 131i ba52 melanoma on-hold-or-discontinued beta-%ce%b2
I-131-CAM-H2 HER2 131I SGMIB Breast cancer In Clinical development beta (β–) Read more her2 131i sgmib breast-cancer in-clinical-development beta-%ce%b2
I-131-chTNT (Vivatuxin) DNA 131I Derlotuximab Brain Cancer, Hepatocarcinoma, Lung Cancer Marketed beta (β–) Read more dna 131i derlotuximab brain-cancer hepatocarcinoma lung-cancer marketed beta-%ce%b2
I-131-ICF01012 Melanin 131I ICF01012 Melanoma Early stage beta (β–) Read more melanin 131i icf01012 melanoma early-stage beta-%ce%b2
I-131-IMAZA Adrenergic tissues 131I Iobenguane Adrenal cell carcinoma (ACC) In Clinical development beta (β–) Read more adrenergic-tissues 131i iobenguane adrenal-cell-carcinoma-acc in-clinical-development beta-%ce%b2
I-131-Iobenguane (MIBG) Adrenergic tissues 131I Iobenguane Neuroblastoma, Neuroendocrine Tumor (NET), Pheochromocytoma Marketed beta (β–) Read more adrenergic-tissues 131i iobenguane neuroblastoma neuroendocrine-tumor-net pheochromocytoma marketed beta-%ce%b2
I-131-Iopofosine PI3K 131I CLR 131 Multiple Myeloma In Clinical development beta (β–) Read more pi3k 131i clr-131 multiple-myeloma in-clinical-development beta-%ce%b2
I-131-Lipiodol Fatty acid containing tissues 131I Lipiodol Hepatocarcinoma Marketed beta (β–) Read more fatty-acid-containing-tissues 131i lipiodol hepatocarcinoma marketed beta-%ce%b2
I-131-Metuximab CD147 131I n/a Hepatocarcinoma Marketed beta (β–) Read more cd147 131i n-a hepatocarcinoma marketed beta-%ce%b2
I-131-Naxitamab GD2 131I Naxitamab Neuroblastoma In Clinical development beta (β–) Read more gd2 131i naxitamab neuroblastoma in-clinical-development beta-%ce%b2
I-131-Omburtamab B7-H3/CD276 131I Omburtamab Neuroblastoma, Soft tissue cancer In Clinical development beta (β–) Read more b7-h3-cd276 131i omburtamab neuroblastoma soft-tissue-cancer in-clinical-development beta-%ce%b2
I-131-RPS-001 PSMA 131I RPS-001 Prostate Cancer In Clinical development beta (β–) Read more psma 131i rps-001 prostate-cancer in-clinical-development beta-%ce%b2
I-131-Sodium Iodide Thyroid tissues 131I n/a Head and Neck Cancer, Thyroid Cancer Marketed beta (β–) Read more thyroid-tissues 131i n-a head-and-neck-cancer thyroid-cancer marketed beta-%ce%b2
I-131-TLX-101 LAT-1 131I Phenylalanine Brain Cancer In Clinical development beta (β–) Read more lat-1 131i phenylalanine brain-cancer in-clinical-development beta-%ce%b2
I-131-TM601 Annexin 131I Chlorotoxin Glioma, Melanoma On hold or discontinued beta (β–) Read more annexin 131i chlorotoxin glioma melanoma on-hold-or-discontinued beta-%ce%b2
I-131-Tositumomab (Bexxar®) CD20 131I Tositumomab Non-Hodgkin's lymphoma (NHL) On hold or discontinued beta (β–) Read more cd20 131i tositumomab non-hodgkins-lymphoma-nhl on-hold-or-discontinued beta-%ce%b2
I-131-Weimeisheng DNA 131I Weimeisheng Lung Cancer Marketed beta (β–) Read more dna 131i weimeisheng lung-cancer marketed beta-%ce%b2
Lu-177-AMTG GRPR 177Lu Bombesin Prostate Cancer Early stage beta (β–) Read more grpr 177lu bombesin prostate-cancer early-stage beta-%ce%b2
Lu-177-CTT-1403 PSMA 177Lu CTT-1403 Prostate Cancer In Clinical development beta (β–) Read more psma 177lu ctt-1403 prostate-cancer in-clinical-development beta-%ce%b2
Lu-177-Debio-1124 CCK2R 177Lu Minigastrin PSIG-2 Thyroid Cancer On hold or discontinued beta (β–) Read more cck2r 177lu minigastrin-psig-2 thyroid-cancer on-hold-or-discontinued beta-%ce%b2
Lu-177-DOTA-EB-FAPi Fibroblasts 177Lu FAPi Solid Tumors, Thyroid Cancer Early stage beta (β–) Read more fibroblasts 177lu fapi solid-tumors thyroid-cancer early-stage beta-%ce%b2
Lu-177-DOTA-EB-TATE Somatostatin receptors 177Lu EB-TATE Head and Neck Cancer, Neuroendocrine Tumor (NET), Thyroid Cancer In Clinical development beta (β–) Read more somatostatin-receptors 177lu eb-tate head-and-neck-cancer neuroendocrine-tumor-net thyroid-cancer in-clinical-development beta-%ce%b2
Lu-177-DOTAZOL Bones 177Lu n/a Pain palliation, Prostate Cancer In Clinical development beta (β–) Read more bones 177lu n-a pain-palliation prostate-cancer in-clinical-development beta-%ce%b2
Lu-177-DPI-4452 CAIX 177Lu DPI-4452 Colorectal Cancer, Pancreas Cancer, Renal Cancer Early stage beta (β–) Read more caix 177lu dpi-4452 colorectal-cancer pancreas-cancer renal-cancer early-stage beta-%ce%b2
Lu-177-DTPA-Omburtamab n/a 177Lu n/a Brain Cancer, Medulloblastoma In Clinical development beta (β–) Read more n-a 177lu n-a brain-cancer medulloblastoma in-clinical-development beta-%ce%b2
Lu-177-EB-PSMA-617 PSMA 177Lu EB-PSMA-617 Prostate Cancer In Clinical development beta (β–) Read more psma 177lu eb-psma-617 prostate-cancer in-clinical-development beta-%ce%b2
Lu-177-Edotreotide (Solucin®) Somatostatin receptors 177Lu Edotreotide Neuroendocrine Tumor (NET) In Clinical development beta (β–) Read more somatostatin-receptors 177lu edotreotide neuroendocrine-tumor-net in-clinical-development beta-%ce%b2
Lu-177-EDTMP Bones 177Lu n/a Bone pain palliation Marketed beta (β–) Read more bones 177lu n-a bone-pain-palliation marketed beta-%ce%b2
Lu-177-FAP-2286 Fibroblasts 177Lu FAP-2286 Solid Tumors In Clinical development beta (β–) Read more fibroblasts 177lu fap-2286 solid-tumors in-clinical-development beta-%ce%b2
Lu-177-FAPI-04 Fibroblasts 177Lu FAPI-04 Solid Tumors Early stage beta (β–) Read more fibroblasts 177lu fapi-04 solid-tumors early-stage beta-%ce%b2
Lu-177-HTK03170 PSMA 177Lu PSMA Prostate Cancer Early stage beta (β–) Read more psma 177lu psma prostate-cancer early-stage beta-%ce%b2
Lu-177-IPN-01087 NTSR1 177Lu IPN-01087 Pancreas Cancer In Clinical development beta (β–) Read more ntsr1 177lu ipn-01087 pancreas-cancer in-clinical-development beta-%ce%b2
Lu-177-iPSMA PSMA 177Lu iPSMA Prostate Cancer Early stage beta (β–) Read more psma 177lu ipsma prostate-cancer early-stage beta-%ce%b2
Lu-177-ITM-31 CAXII 177Lu Fab Glioblastoma Early stage beta (β–) Read more caxii 177lu fab glioblastoma early-stage beta-%ce%b2
Lu-177-Lilotomab Satetraxetan (Betalutin) CD37 177Lu n/a Non-Hodgkin's lymphoma (NHL) On hold or discontinued beta (β–) Read more cd37 177lu n-a non-hodgkins-lymphoma-nhl on-hold-or-discontinued beta-%ce%b2
Lu-177-LNC1004 Fibroblasts 177Lu FAPi Solid Tumors Early stage beta (β–) Read more fibroblasts 177lu fapi solid-tumors early-stage beta-%ce%b2
Lu-177-LNC1010 Somatostatin receptors 177Lu Peptide Neuroendocrine Tumor (NET) Early stage beta (β–) Read more somatostatin-receptors 177lu peptide neuroendocrine-tumor-net early-stage beta-%ce%b2
Lu-177-Ludotadipep PSMA 177Lu PSMA Prostate Cancer Early stage beta (β–) Read more psma 177lu psma prostate-cancer early-stage beta-%ce%b2
Lu-177-MVT-1075 sLea 177Lu MVT-1075 Pancreas Cancer In Clinical development beta (β–) Read more slea 177lu mvt-1075 pancreas-cancer in-clinical-development beta-%ce%b2
Lu-177-Oxodotreotide (Lutathera®) Somatostatin receptors 177Lu Oxodotreotide Neuroendocrine Tumor (NET) Marketed beta (β–) Read more somatostatin-receptors 177lu oxodotreotide neuroendocrine-tumor-net marketed beta-%ce%b2
Lu-177-Pentixather CXCR4 177Lu Pentixather Multiple Myeloma, Solid Tumors In Clinical development beta (β–) Read more cxcr4 177lu pentixather multiple-myeloma solid-tumors in-clinical-development beta-%ce%b2
Lu-177-PNT2002 PSMA 177Lu PSMA-I&T Prostate Cancer In Clinical development beta (β–) Read more psma 177lu psma-it prostate-cancer in-clinical-development beta-%ce%b2
Lu-177-PNT6555 Fibroblasts 177Lu FAPi Solid Tumors Early stage beta (β–) Read more fibroblasts 177lu fapi solid-tumors early-stage beta-%ce%b2
Lu-177-PSMA-ALB-56 PSMA 177Lu PSMA-ALB-56 Prostate Cancer Early stage beta (β–) Read more psma 177lu psma-alb-56 prostate-cancer early-stage beta-%ce%b2
Lu-177-PSMA-R2 PSMA 177Lu PSMA-R2 Prostate Cancer In Clinical development beta (β–) Read more psma 177lu psma-r2 prostate-cancer in-clinical-development beta-%ce%b2
Lu-177-rhPSMA-10.1 PSMA 177Lu PSMA Prostate Cancer In Clinical development beta (β–) Read more psma 177lu psma prostate-cancer in-clinical-development beta-%ce%b2
Lu-177-Rituximab CD20 177Lu Rituximab Non-Hodgkin's lymphoma (NHL) Early stage beta (β–) Read more cd20 177lu rituximab non-hodgkins-lymphoma-nhl early-stage beta-%ce%b2
Lu-177-RM2 GRPR 177Lu Bombesin Prostate Cancer In Clinical development beta (β–) Read more grpr 177lu bombesin prostate-cancer in-clinical-development beta-%ce%b2
Lu-177-Rosopatamab PSMA 177Lu Rosopatamab Prostate Cancer In Clinical development beta (β–) Read more psma 177lu rosopatamab prostate-cancer in-clinical-development beta-%ce%b2
Lu-177-Satoreotide tetraxetan Somatostatin receptors 177Lu Satoreotide Neuroendocrine Tumor (NET) In Clinical development beta (β–) Read more somatostatin-receptors 177lu satoreotide neuroendocrine-tumor-net in-clinical-development beta-%ce%b2
Lu-177-ST2210 (IART – Lu-177 DOTA-Biotin) Avidin 177Lu Biotin Breast cancer, Colon cancer On hold or discontinued beta (β–) Read more avidin 177lu biotin breast-cancer colon-cancer on-hold-or-discontinued beta-%ce%b2
Lu-177-TLX250 CAIX 177Lu Girentuximab Kidney Cancer In Clinical development beta (β–) Read more caix 177lu girentuximab kidney-cancer in-clinical-development beta-%ce%b2
Lu-177-Vipivotide tetraxetan (Pluvicto™) PSMA 177Lu Vipivotide Prostate Cancer Marketed beta (β–) Read more psma 177lu vipivotide prostate-cancer marketed beta-%ce%b2
Lu-177-XT033 PSMA 177Lu Peptide Prostate Cancer Early stage beta (β–) Read more psma 177lu peptide prostate-cancer early-stage beta-%ce%b2
P-32-Colloidal Chromic Phosphate Bones 32P n/a Brain Cancer, Rheumatology, Solid Tumors Marketed beta (β–) Read more bones 32p n-a brain-cancer rheumatology solid-tumors marketed beta-%ce%b2
P-32-OncoSil Brachytherapy 32P n/a Pancreas Cancer Marketed beta (β–) Read more brachytherapy 32p n-a pancreas-cancer marketed beta-%ce%b2
P-32-Sodium Phosphate Bones 32P n/a Bone pain palliation, Polycythemia vera Marketed beta (β–) Read more bones 32p n-a bone-pain-palliation polycythemia-vera marketed beta-%ce%b2
Pb-212-ADVC001 PSMA 212Pb Peptide Prostate Cancer Early stage alpha (α) Read more psma 212pb peptide prostate-cancer early-stage alpha-%ce%b1
Pb-212-DOTAMTATE Somatostatin receptors 212Pb Dotamtate Neuroendocrine Tumor (NET) In Clinical development alpha (α) Read more somatostatin-receptors 212pb dotamtate neuroendocrine-tumor-net in-clinical-development alpha-%ce%b1
Pb-212-GRPR GRPR 212Pb Bombesin Solid Tumors Early stage alpha (α) Read more grpr 212pb bombesin solid-tumors early-stage alpha-%ce%b1
Pb-212-VMT-α-NET Somatostatin receptors 212Pb Peptide Neuroendocrine Tumor (NET) Early stage alpha (α) Read more somatostatin-receptors 212pb peptide neuroendocrine-tumor-net early-stage alpha-%ce%b1
Pb-212-VMT01 MCR1 212Pb VMT01 Melanoma Early stage alpha (α) Read more mcr1 212pb vmt01 melanoma early-stage alpha-%ce%b1
Ra-223-Radium Dichloride Bones 223Ra n/a Bone pain palliation Marketed alpha (α) Read more bones 223ra n-a bone-pain-palliation marketed alpha-%ce%b1
Ra-224-Radium Chloride (224-SpondylAT®) Brachytherapy 224Ra n/a Ankylosing Spondylitis On hold or discontinued alpha (α) Read more brachytherapy 224ra n-a ankylosing-spondylitis on-hold-or-discontinued alpha-%ce%b1
Ra-224-RadSpherin Brachytherapy 224Ra n/a Colon cancer, Ovarian Cancer In Clinical development alpha (α) Read more brachytherapy 224ra n-a colon-cancer ovarian-cancer in-clinical-development alpha-%ce%b1
Re-186-Rhenium Etidronate (HEDP) Bones 186Re n/a Bone pain palliation Marketed beta (β–) Read more bones 186re n-a bone-pain-palliation marketed beta-%ce%b2
Re-186-Rhenium Sulfide Brachytherapy 186Re n/a Rheumatology Marketed beta (β–) Read more brachytherapy 186re n-a rheumatology marketed beta-%ce%b2
Re-186-RNL Brachytherapy 186Re n/a Glioblastoma In Clinical development beta (β–) Read more brachytherapy 186re n-a glioblastoma in-clinical-development beta-%ce%b2
Re-188-Dendrimer (ImDendrim) Brachytherapy 188Re n/a Hepatocarcinoma Early stage beta (β–) Read more brachytherapy 188re n-a hepatocarcinoma early-stage beta-%ce%b2
Re-188-Etidronate (HEDP) Bones 188Re n/a Bone pain palliation, Rheumatology Marketed beta (β–) Read more bones 188re n-a bone-pain-palliation rheumatology marketed beta-%ce%b2
Re-188-P2045 (Tozaride) Somatostatin receptors 188Re Tozaride Lung Cancer, Pancreas Cancer In Clinical development beta (β–) Read more somatostatin-receptors 188re tozaride lung-cancer pancreas-cancer in-clinical-development beta-%ce%b2
Re-188-Rhenium Lipiodol Fatty acid containing tissues 188Re Lipiodol Hepatocarcinoma Marketed beta (β–) Read more fatty-acid-containing-tissues 188re lipiodol hepatocarcinoma marketed beta-%ce%b2
Re-188-Rhenium Skin Cancer Therapy Brachytherapy 188Re n/a Non-Melanoma skin cancer Marketed beta (β–) Read more brachytherapy 188re n-a non-melanoma-skin-cancer marketed beta-%ce%b2
Re-188-Rhenium Sulfide Brachytherapy 188Re n/a Rheumatology Marketed beta (β–) Read more brachytherapy 188re n-a rheumatology marketed beta-%ce%b2
Re-188-SSS/Lipiodol Fatty acid containing tissues 188Re Lipiodol Liver cancer In Clinical development beta (β–) Read more fatty-acid-containing-tissues 188re lipiodol liver-cancer in-clinical-development beta-%ce%b2
Sm-153-DOTMP (CycloSAM) Bones 153Sm n/a Bone pain palliation In Clinical development beta (β–) Read more bones 153sm n-a bone-pain-palliation in-clinical-development beta-%ce%b2
Sm-153-Lexidronam (EDTMP) Bones 153Sm n/a Bone pain palliation Marketed beta (β–) Read more bones 153sm n-a bone-pain-palliation marketed beta-%ce%b2
Sm-153-Oxabiphor (ETMP) Bones 153Sm n/a Bone pain palliation Marketed beta (β–) Read more bones 153sm n-a bone-pain-palliation marketed beta-%ce%b2
Sn-117m-DOTA-Annexin-V Annexin 117mSn Annexin-V Rheumatology, Vulnerable plaque In Clinical development C.E. (Conversion Electron) Read more annexin 117msn annexin-v rheumatology vulnerable-plaque in-clinical-development c-e-conversion-electron
Sn-117m-DTPA Bones 117mSn n/a Bone pain palliation In Clinical development C.E. (Conversion Electron) Read more bones 117msn n-a bone-pain-palliation in-clinical-development c-e-conversion-electron
Sn-117m-HTC (Synovetin) Brachytherapy 117mSn n/a Rheumatology Marketed C.E. (Conversion Electron) Read more brachytherapy 117msn n-a rheumatology marketed c-e-conversion-electron
Sr-89-Strontium Chloride Bones 89Sr n/a Bone pain palliation Marketed beta (β–) Read more bones 89sr n-a bone-pain-palliation marketed beta-%ce%b2
Tb-161-PSMA-I&T PSMA 161Tb PSMA-I&T Prostate Cancer Early stage beta (β–) Read more psma 161tb psma-it prostate-cancer early-stage beta-%ce%b2
Th-227-Anetumab corixetan Mesothelin 227Th Anetumab Ovarian Cancer, Solid Tumors Early stage alpha (α) Read more mesothelin 227th anetumab ovarian-cancer solid-tumors early-stage alpha-%ce%b1
Th-227-Epratuzumab (Th-227-BAY1862864) CD22 227Th Epratuzumab Non-Hodgkin's lymphoma (NHL) On hold or discontinued alpha (α) Read more cd22 227th epratuzumab non-hodgkins-lymphoma-nhl on-hold-or-discontinued alpha-%ce%b1
Th-227-Pelgifatamab PSMA 227Th PSMA Prostate Cancer Early stage alpha (α) Read more psma 227th psma prostate-cancer early-stage alpha-%ce%b1
Y-90-Anditixafortide CXCR4 90Y Pentixather Multiple Myeloma, Solid Tumors In Clinical development beta (β–) Read more cxcr4 90y pentixather multiple-myeloma solid-tumors in-clinical-development beta-%ce%b2
Y-90-Basixilimab CD25 90Y Basixilimab Hodgkin's Lymphoma (HL), Non-Hodgkin's lymphoma (NHL) In Clinical development beta (β–) Read more cd25 90y basixilimab hodgkins-lymphoma-hl non-hodgkins-lymphoma-nhl in-clinical-development beta-%ce%b2
Y-90-Besilesomab CD66 90Y Besilesomab Amyloidosis In Clinical development beta (β–) Read more cd66 90y besilesomab amyloidosis in-clinical-development beta-%ce%b2
Y-90-Betaglue Brachytherapy 90Y n/a Breast cancer, Hepatocellular Carcinoma (HCC), Solid Tumors In Clinical development beta (β–) Read more brachytherapy 90y n-a breast-cancer hepatocellular-carcinoma-hcc solid-tumors in-clinical-development beta-%ce%b2
Y-90-Carbon Microspheres Brachytherapy 90Y n/a Hepatocarcinoma In Clinical development beta (β–) Read more brachytherapy 90y n-a hepatocarcinoma in-clinical-development beta-%ce%b2
Y-90-Daclizumab (HAT) CD25 90Y Daclizumab Leukemia, Non-Hodgkin's lymphoma (NHL) On hold or discontinued beta (β–) Read more cd25 90y daclizumab leukemia non-hodgkins-lymphoma-nhl on-hold-or-discontinued beta-%ce%b2
Y-90-DOTA-FF-21101 IGF-1R 90Y p-cadherin Biliary Tract Cancer, Head and Neck Cancer, Ovarian Cancer Early stage beta (β–) Read more igf-1r 90y p-cadherin biliary-tract-cancer head-and-neck-cancer ovarian-cancer early-stage beta-%ce%b2
Y-90-DOTALAN (Lanreotide) Somatostatin receptors 90Y Lanreotide Neuroendocrine Tumor (NET) On hold or discontinued beta (β–) Read more somatostatin-receptors 90y lanreotide neuroendocrine-tumor-net on-hold-or-discontinued beta-%ce%b2
Y-90-DOTATOC (Edotreotide) Somatostatin receptors 90Y Edotreotide Neuroendocrine Tumor (NET) On hold or discontinued beta (β–) Read more somatostatin-receptors 90y edotreotide neuroendocrine-tumor-net on-hold-or-discontinued beta-%ce%b2
Y-90-Epratuzumab Tetratexan CD22 90Y Epratuzumab Non-Hodgkin's lymphoma (NHL) On hold or discontinued beta (β–) Read more cd22 90y epratuzumab non-hodgkins-lymphoma-nhl on-hold-or-discontinued beta-%ce%b2
Y-90-FAPI-04 Fibroblasts 90Y FAPI-04 Solid Tumors Early stage beta (β–) Read more fibroblasts 90y fapi-04 solid-tumors early-stage beta-%ce%b2
Y-90-FAPI-46 Fibroblasts 90Y FAPI-46 Tumor growth In Clinical development beta (β–) Read more fibroblasts 90y fapi-46 tumor-growth in-clinical-development beta-%ce%b2
Y-90-Ferritarg Ferritin 90Y Ferritarg Hodgkin's Lymphoma (HL) On hold or discontinued beta (β–) Read more ferritin 90y ferritarg hodgkins-lymphoma-hl on-hold-or-discontinued beta-%ce%b2
Y-90-Ibritumomab Tiuxetan IGF-1R 90Y Ibritumomab Biliary Tract Cancer, Head and Neck Cancer, Ovarian Cancer Preclinical beta (β–) Read more igf-1r 90y ibritumomab biliary-tract-cancer head-and-neck-cancer ovarian-cancer preclinical beta-%ce%b2
Y-90-IsoPet – Y-90-RadioGel Brachytherapy 90Y n/a Solid Tumors Marketed beta (β–) Read more brachytherapy 90y n-a solid-tumors marketed beta-%ce%b2
Y-90-Microspheres Brachytherapy 90Y n/a Hepatocarcinoma Marketed beta (β–) Read more brachytherapy 90y n-a hepatocarcinoma marketed beta-%ce%b2
Y-90-OPS201 (SOMTher®) Somatostatin receptors 90Y OPS201 Neuroendocrine Tumor (NET) On hold or discontinued beta (β–) Read more somatostatin-receptors 90y ops201 neuroendocrine-tumor-net on-hold-or-discontinued beta-%ce%b2
Y-90-Tabituximab barzuxetan FZD10 90Y OTSA101 Synovial sarcoma Early stage beta (β–) Read more fzd10 90y otsa101 synovial-sarcoma early-stage beta-%ce%b2
Y-90-Yttrium Citrate Brachytherapy 90Y n/a Rheumatology Marketed beta (β–) Read more brachytherapy 90y n-a rheumatology marketed beta-%ce%b2

Page load link

Go to Top

Automated page speed optimizations for fast site performance